Sathianathen NJ, Dahm P, Brown SJ, Oestreich M, Gupta S, Konety BR, Kunath F (2019)
Publication Type: Journal article
Publication year: 2019
Book Volume: 2019
Article Number: CD013245
Journal Issue: 1
DOI: 10.1002/14651858.CD013245
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of early abiraterone acetate in combination with androgen deprivation therapy for newly diagnosed metastatic hormone-sensitive prostate cancer.
APA:
Sathianathen, N.J., Dahm, P., Brown, S.J., Oestreich, M., Gupta, S., Konety, B.R., & Kunath, F. (2019). Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer. Cochrane Database of Systematic Reviews, 2019(1). https://doi.org/10.1002/14651858.CD013245
MLA:
Sathianathen, Niranjan J., et al. "Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer." Cochrane Database of Systematic Reviews 2019.1 (2019).
BibTeX: Download